Sana Posts $20.4M Q3 Profit on Contingent Consideration Gain, Cash Down to $121.7M
SANA is trading near its 52-week low of $2.22 (8.6% above the low).
Summary
Sana reported Q3 2026 GAAP net income of $20.4 million, or $0.07 per share, versus a $42.2 million loss a year earlier — but the swing is almost entirely a $63.4 million non-cash gain from remeasuring success payment and Cobalt contingent consideration liabilities after the August 2026 amendment. Non-GAAP net loss was $43.0 million, or $0.14 per share, slightly wider than the $39.0 million loss in Q3 2025 as R&D rose to $33.9 million on SC451 and SG293 manufacturing costs. Cash, equivalents and marketable securities fell to $121.7 million from $138.4 million at year-end 2025, with the company guiding runway into mid-2027 — a tighter window than the mid-2027-plus framing that followed Q2, and the going-concern backdrop from the August 10-Q remains the key constraint. On the pipeline, Sana still expects to file the SC451 IND and start a Phase 1/2 type 1 diabetes trial as early as this year, with SG293 first-in-human data in non-Hodgkin lymphoma as early as the first half of 2027, and it published 14-month UP421 hypoimmune islet data in a NEJM Letter to the Editor. Watch the SC451 IND filing and trial start, which the company says could come before year-end.
At the time of this announcement, SANA was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $700.5M. The 52-week trading range was $2.22 to $5.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.